GI Dynamics announced today that results from a registry for its EndoBarrier for type 2 diabetes were positive.
Data from use of the EndoBarrier within the National Health Service (NHS) in the UK were presented by Dr. Robert Ryder of City Hospital (Birmingham, UK) at the American Diabetes Association Scientific Sessions last month, according to a news release.
Boston-based GI Dynamics designed its EndoBarrier endoscopically delivered device therapy as a non-surgical, alternative treatment for type 2 diabetes and obesity for patients who do not have adequate control of their conditions through their current medication and lifestyle. Previous studies have demonstrated that the device met trial safety and efficacy endpoints.
GI Dynamics’ ABCD worldwide EndoBarrier registry, led by Dr. Ryder, collected data from 33 centers in nine countries, with data entered on 1,001 patients as of December 2021.
“In these analyses, the data highlight clinically significant reductions in HbA1c showing 1.3% absolute mean reduction Worldwide and a 1.9% mean reduction in the UK, even though there were many patients without diabetes or with good glycemic control. In addition, we also saw a 13.3kg mean reduction in weight worldwide and 17.3kg mean reduction in the UK study along with improved associated cardiovascular metrics and systolic blood pressure,” Ryder said in a news release. “When considering the overall clinical benefit of EndoBarrier treatment with the acceptable risk profile, the data combines to present a positive case for treatment of patients with type 2 diabetes and obesity.”
